Bristol Myers Squibb Company $BMY Shares Purchased by DNB Asset Management AS

DNB Asset Management AS raised its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 3.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 703,651 shares of the biopharmaceutical company’s stock after acquiring an additional 26,719 shares during the quarter. DNB Asset Management AS’s holdings in Bristol Myers Squibb were worth $31,735,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Gateway Investment Advisers LLC increased its position in Bristol Myers Squibb by 10.0% in the 3rd quarter. Gateway Investment Advisers LLC now owns 113,457 shares of the biopharmaceutical company’s stock worth $5,117,000 after purchasing an additional 10,284 shares during the last quarter. CWA Asset Management Group LLC grew its stake in shares of Bristol Myers Squibb by 25.9% in the 3rd quarter. CWA Asset Management Group LLC now owns 150,359 shares of the biopharmaceutical company’s stock valued at $6,781,000 after buying an additional 30,909 shares in the last quarter. Commonwealth Retirement Investments LLC increased its holdings in Bristol Myers Squibb by 24.6% in the second quarter. Commonwealth Retirement Investments LLC now owns 59,183 shares of the biopharmaceutical company’s stock worth $2,740,000 after buying an additional 11,690 shares during the last quarter. Stephens Inc. AR raised its position in Bristol Myers Squibb by 13.5% during the third quarter. Stephens Inc. AR now owns 273,343 shares of the biopharmaceutical company’s stock valued at $12,328,000 after acquiring an additional 32,476 shares in the last quarter. Finally, Railway Pension Investments Ltd lifted its stake in Bristol Myers Squibb by 3.7% in the third quarter. Railway Pension Investments Ltd now owns 1,139,600 shares of the biopharmaceutical company’s stock valued at $51,396,000 after acquiring an additional 40,300 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Positive Phase III interim topline results reported for izalontamab brengitecan (Iza‑bren) in previously treated unresectable locally advanced/metastatic triple‑negative breast cancer — the readout validates an ADC Bristol Myers licensed and could materially boost future revenue potential (deal carries >$8B long‑term economics that BMS has highlighted), which is likely the main driver lifting sentiment today. Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer
• Neutral Sentiment: Coverage pieces note BMY has lagged the Nasdaq over the last year, but Wall Street remains moderately optimistic — this frames today’s rally as driven more by idiosyncratic clinical news than by broad market leadership. Is Bristol-Myers Squibb Stock Underperforming the Nasdaq?
• Neutral Sentiment: Sector updates and analyst writeups (momentum/value profiles) are highlighting BMY as a top‑ranked momentum/value/dividend candidate for different investor styles — these stories can attract additional retail and income‑oriented flows but are not major catalysts by themselves. Bristol Myers Squibb (BMY) is a Top-Ranked Momentum Stock: Should You Buy?
• Neutral Sentiment: General pharma‑sector coverage and updates mention BMY among large‑cap players with deep late‑stage pipelines — supportive context but not a standalone catalyst. Bristol Myers Squibb (NYSE:BMY) Update Pharma Sector Developments
• Negative Sentiment: RBC Capital initiated coverage with a Sector Perform rating and a $60 price target (implying slight downside versus recent levels); that cautious initiation caps upside for some investors and may limit the size of gains if broader sentiment cools. RBC Capital Initiates Bristol Myers (BMY) with $60 Target

Analyst Ratings Changes

Several research analysts have recently commented on the stock. The Goldman Sachs Group restated a “neutral” rating and set a $57.00 price target (up from $51.00) on shares of Bristol Myers Squibb in a research note on Tuesday, December 2nd. Cantor Fitzgerald reissued a “neutral” rating on shares of Bristol Myers Squibb in a research report on Monday, November 24th. Leerink Partners boosted their price target on Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Barclays started coverage on Bristol Myers Squibb in a report on Thursday, February 19th. They set an “overweight” rating and a $75.00 price objective on the stock. Finally, Guggenheim restated a “buy” rating and issued a $72.00 target price (up from $62.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. Nine investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $60.71.

Bristol Myers Squibb Trading Up 1.9%

Bristol Myers Squibb stock opened at $62.23 on Friday. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $63.33. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. The firm has a market capitalization of $126.74 billion, a PE ratio of 18.04, a PEG ratio of 0.17 and a beta of 0.29. The business’s 50-day simple moving average is $56.98 and its 200-day simple moving average is $50.52.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The business had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. During the same period last year, the business earned $1.67 EPS. The business’s quarterly revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Equities research analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Friday, January 2nd were paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.0%. The ex-dividend date was Friday, January 2nd. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio is currently 73.04%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.